See What HealthDay Can Do For You
Contact Us

Zingo Offers Pain Relief During Child Injections

Approved for patients aged 3 to 18

FRIDAY, Aug. 17, 2007 (HealthDay News) -- The pain-relieving drug Zingo (lidocaine hydrochloride) has been approved by the U.S. Food and Drug Administration for children aged 3 to 18 who have "venous access" procedures such as IV insertions or blood draws, maker Anesiva Inc. said Friday.

The fast-acting, no-needle treatment contains sterile lidocaine powder that is applied topically and begins working in one to three minutes, the company said in a statement.

In clinical testing involving 1,109 patients, common side effects of Zingo included redness and swelling at the application site.

More than 18 million pediatric venous access procedures are performed annually, Anesiva said. The company said it is also evaluating the drug's use in adults.

More information

To learn more about pediatric medical procedures and pain, visit the University of Michigan Health System.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.